OptimizeRx Corp. (NASDAQ:OPRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have received an average rating of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $17.5714.

OPRX has been the topic of several research analyst reports. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. B. Riley Financial reissued a “buy” rating and issued a $11.00 price target (down from $28.00) on shares of OptimizeRx in a research note on Friday, March 6th. Stifel Nicolaus cut their price target on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday. Finally, Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its position in shares of OptimizeRx by 600.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after acquiring an additional 1,818 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx during the second quarter worth approximately $44,000. BNP Paribas Financial Markets raised its stake in OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in OptimizeRx in the 4th quarter valued at $62,000. Finally, USA Financial Formulas purchased a new position in OptimizeRx in the 3rd quarter valued at $131,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Trading Down 3.8%

OPRX stock opened at $6.58 on Wednesday. OptimizeRx has a 52-week low of $3.99 and a 52-week high of $22.25. The company has a quick ratio of 3.05, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. The firm has a market cap of $122.65 million, a P/E ratio of 25.31 and a beta of 1.20. The company’s 50-day simple moving average is $10.29 and its 200-day simple moving average is $14.58.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. As a group, equities analysts forecast that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx declared that its Board of Directors has authorized a share buyback plan on Thursday, March 5th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.